Jul. 4 at 12:11 PM
$NWBO Bottom line: The July 3 PSM analyses meaningfully strengthen the evidence for a clear DCVax-L treatment effect in GBM by rigorously validating survival benefits beyond the original external-control design. This is positive for the ongoing UK regulatory processes (MHRA MAA under review; NICE appraisal), though approval timelines remain uncertain and not guaranteed. The DCVax platform has conceptual and early clinical breadth beyond GBM. Andrew Caravello’s X content, preprint, and related writings directly engage with and contextualize these exact topics from a scientific/mechanistic perspective.
This is based on publicly available information as of early July 2026. For the latest official updates, check NWBIO’s website, MHRA/NICE sites, or peer-reviewed publications. Consult qualified medical professionals for any treatment-related decisions.